Hereditary neuralgic amyotrophy (HNA), also known as amytrophic lateral sclerosis (ALS) or Stevens disease, is a rare inherited disorder that primarily causes progressive muscle weakness and atrophy. The disorder is a syndrome resulting from the degeneration of motor neurons in the anterior horns of the spinal cord and brainstem. Clinical manifestations of HNA include impaired control of muscle movement, which can lead to difficulty performing daily activities, decreased respiratory function, and a deterioration in the quality of life of patients.
History of the disease and interesting historical facts
The history of NNA research spans over a hundred years. The first cases were described at the beginning of the 20th century, when neurologists began to associate the symptoms of progressive muscle weakness with damage to motor neurons. In the 1950s, it was established that this disease can be inherited. Its connection with certain genetic mutations was only identified at the end of the 20th century, which greatly changed the approach to diagnosis and treatment. An important step was the discovery of a mutation in the SOD1 gene, which made it possible to develop molecular genetic tests for the diagnosis of NNA, and also became the basis for the development of new treatment methods.
Epidemiology
Hereditary neuralgic amyotrophy is considered a rare disease, and its prevalence varies depending on the population and geographic region. According to epidemiological studies, the incidence of HNA is approximately 1 case per 100,000 people per year. The disease is most common in people of European descent, while its prevalence is significantly lower among African and Asian populations.
Genetic predisposition to this disease
Hereditary neuralgic amyotrophy has a clear genetic predisposition. The main genes involved include:
- SOD1 — mutations in this gene are one of the most studied causes of NAI.
- FGFR1 - is important in the development of the nervous system and is also associated with forms of NNA.
- NEFL - mutations can lead to disruption of neurofilament formation.
The exact mechanisms leading to the following clinical manifestations are not yet fully understood, but are thought to range from disturbances in cellular metabolism to destruction of neuronal structures.
Risk factors for the development of this disease
Risk factors for hereditary neuralgic amyotrophy are mainly related to genetic predisposition, however, there are several relevant aspects that may increase this risk:
- Heredity — the presence of cases of NNA in the family significantly increases the likelihood of the disease.
- Physical factors - Some studies show a link with exposure to heavy physical activity.
- Chemical factors - exposure to heavy metals and toxic chemicals increases the risk of developing the disease.
- Impact of infections - some viral infections may precede the onset of NSAID symptoms.
Diagnosis of this disease
Diagnosis of hereditary neuralgic amyotrophy requires a comprehensive approach, including:
- Main symptoms - progressive muscle weakness, atrophy and muscle fasciculations.
- Laboratory research - blood tests for inflammation and toxicity markers; genetic testing to identify mutations.
- Radiological examinations — magnetic resonance imaging (MRI) to exclude other pathologies.
- Other types of diagnostics — electromyography (EMG) and angiography.
- Differential diagnosis - exclusion of other neuropathies and myopathies, such as venous congestion syndrome and myasthenia gravis.
Treatment
Treatment of hereditary neuralgic amyotrophy remains a complex task. It includes several areas:
- General treatment — rehabilitation programs aimed at maintaining muscle function and strength.
- Pharmacological treatment — use of non-steroidal anti-inflammatory drugs, neuroprotectors.
- Surgical treatment — in some cases, the possibility of surgical intervention to correct pain syndrome may be considered.
- Other types of treatment - physiotherapy and special training to improve physical activity.
List of medications used to treat this disease
The main drugs used to treat NAI include:
- Rilutsol
- Gabapentin
- Tizanidin
- Baclofen
Disease monitoring
Monitoring the condition of patients with NNA includes several key aspects:
- Control stages - regular examinations by a neurologist to assess the progression of the disease.
- Forecast — depending on the rate of progression, it can vary from several years to decades.
- Complications - respiratory complications and increased risk of infectious diseases.
Age-related features of the disease
The progression of hereditary neuralgic amyotrophy can vary markedly depending on the age group. In children, symptoms may develop more slowly, while in adults the disease progresses much more rapidly, resulting in more severe muscle wasting.
Questions and Answers
- What is the main cause of NNA? — The main cause is genetic mutations in specific genes such as SOD1 and NEFL.
- Can hereditary neuralgic amyotrophy be prevented? — There are currently no established preventive measures, but early diagnosis can help slow down progression.
- What is the life expectancy of patients with NNA? — Life expectancy can vary, on average it is 2-5 years after the onset of symptoms, but some patients live much longer.
- Which treatment is most effective? — Treatment includes the use of riluzol, as well as rehabilitation measures to improve the quality of life.
- What types of rehabilitation are recommended? — Physical therapy and rehabilitation sessions are recommended to maintain muscle function and strength.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov shares recommendations for patients with NNA:
- Monitor your symptoms and see your doctor if they progress.
- Engage in physical therapy to help maintain muscle tone.
- Maintain a healthy diet and avoid toxic substances that may worsen the condition.
- Take an active part in rehabilitation programs to maintain your quality of life.
Support from professionals and loved ones can significantly improve the quality of life of patients with hereditary neuralgic amyotrophy and help them cope with the challenges of this complex disease.
